[A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis]

I A Zavalishin; A V Peresedova; N I Stoĭda; O iu Rebrova; M N Zakharova; L S Adarcheva; A S Niazbekova; L Sh Askarova; E V Baĭdina

[A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis]

Zh Nevrol Psikhiatr Im S S Korsakova. 2006:Spec No 3:111-5.

[Article in Russian]

Authors

I A Zavalishin, A V Peresedova, N I Stoĭda, O iu Rebrova, M N Zakharova, L S Adarcheva, A S Niazbekova, L Sh Askarova, E V Baĭdina

PMID: 17172245

Abstract

A comparative analysis of efficacy and tolerability of such immunomodulating compounds as rebif 22-mcg and copaxone used in the treatment of multiple sclerosis is presented. The analysis was based on the data obtained in the 2-year study of copaxone (145 patients) and rebif 22-mcg (74 patients) therapy carried out in the Neurology Institute, Russian Academy of Medical Sciences.

Publication types

Comparative Study
English Abstract

MeSH terms

Adjuvants, Immunologic / administration & dosage
Adjuvants, Immunologic / therapeutic use*
Adult
Drug Administration Schedule
Female
Glatiramer Acetate
Humans
Interferon beta-1a
Interferon-beta / administration & dosage
Interferon-beta / therapeutic use*
Male
Multiple Sclerosis / drug therapy*
Peptides / therapeutic use*

Substances

Adjuvants, Immunologic
Peptides
Glatiramer Acetate
Interferon-beta
Interferon beta-1a